US to accelerate development of Mapp's Ebola treatment US to accelerate development of Mapp's Ebola treatment 
				Center for Disease Control | Getty Images
				In this handout from the Center for Disease Control, a colorized transmission electron micrograph (TEM) of a Ebola virus virion is seen.
	
	
																
			
									  A U.S. government agency said on Tuesday that it would accelerate the development of an Ebola treatment from Mapp Biopharmaceutical.   The U.S. Department of Health and Human Services said that work on the Ebola drug would be funded by a contract worth up to $42.3 million.   It said that Mapp would manufacture a small amount of the drug for early stage safety studies. Read More  German ship line imposes Ebola fee on Africa shipments   â€”By Reuters 